BMS-986288 continues to be evaluated in a Phase 1 clinical study. We expect initial data to be available in the fourth quarter of 2021. 8226; Applicability across many molecular targets. Adverse events were consistent with data previously reported. Additionally, CX-904 is predicted to be tolerated at efficacious doses in humans. Changing the formulation and scale up process is a complicated and difficult task. This could result in a substantial delay of our clinical trials. We also rely on trade secret protection for our confidential and proprietary information. A biological product can also obtain pediatric market exclusivity in the United States. The BPCIA is complex and continues to be interpreted and implemented by the FDA. We maintain our executive offices at 151 Oyster Point Blvd., Additional funds may not be available to us on acceptable terms or at all. In March 2020, we made the strategic decision to terminate that trial. Finally, numerous small companies are also working in the space. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. Furthermore, the payment of these severance benefits could harm our financial condition. As a public company, we incur significant legal, accounting and other expenses. We have never declared or paid cash dividends on our capital stock.
